Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511886-12-00

Acronym

2020-004195-17

Enrollment

146

Registered

2024-04-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unfavorable intermediate/high risk prostate cancer patients

Brief summary

The primary objective of the study is 3-yr bNED survival.

Detailed description

Overall survival

Interventions

DRUGBICALUTAMIDE

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary objective of the study is 3-yr bNED survival.	—

Secondary

Measure	Time frame
Overall survival	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026